Discovery of Aficamten (CK-274): Next-in-class Cardiac myosin inhibitor (CMI) for obstructive Hypertrophic Cardiomyopathy (oHCM)

Cardiac Myosin Inhibitor, CK-586, Minimally Reduces Systolic Function and Ameliorates Obstruction in Feline Hypertrophic Cardiomyopathy

Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness

Pharmacokinetics, Excretion, and Metabolism of [14C]Aficamten Following Single Oral Dose Administration to Rats

Preclinical Pharmacokinetics of CK-4021586, a Novel Inhibitor of Cardiac Myosin, and Prediction of Human Pharmacokinetics

Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats

Acute Treatment With Aficamten Rescues Contractile Function in a Myopod® Engineered Heart Tissue Model of Hypertrophic Cardiomyopathy

Preclinical Characterization of CK-4021586, a New Class of Cardiac Myosin Inhibitors for the Treatment of Hypertrophic Cardiomyopathy

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Pharmacokinetics of a Single Dose of Aficamten (CK-274) on Cardiac Contractility in a A31P MYBPC3 Hypertrophic Cardiomyopathy Cat Model